Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Active, not recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Nodule Solitary PulmonaryNon-small Cell Carcinoma
Trial Locations (25)

10029

Mount Sinai Health System, New York

11042

Northwell Health, New York

20010

MedStar, Washington D.C.

21205

The Johns Hopkins University, Baltimore

23219

Virginia Commonwealth University, Richmond

27103

Southeastern Research Center, Winston-Salem

27599

The University of North Carolina, Chapel Hill

27705

Duke University, Durham

29401

Ralph H Johnson VA Medical Center, Charleston

29425

Medical University of South Carolina, Charleston

29605

Prisma Health, Greenville

43210

The Ohio State University, Coulmbus

44195

Cleveland Clinic, Cleveland

46202

Indiana University, Indianapolis

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

63110

The Washington University, St Louis

75390

University of Texas Southwestern, Dallas

77555

University of Texas Medical Branch, Galveston

80045

University of Colorado, Aurora

97220

The Oregon Clinic, Portland

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess, Boston

T2W 1S7

University of Calgary, Calgary

H3H 2R9

McGill University Health Centre, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biodesix, Inc.

INDUSTRY

NCT04171492 - Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules | Biotech Hunter | Biotech Hunter